RITALIN-SR
Clinical safety rating
cautionComprehensive clinical and safety monograph for RITALIN-SR (RITALIN-SR).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid; minor metabolism via CYP2D6. |
| Excretion | Primarily renal (90%) as metabolites including ritalinic acid, with 1-3% unchanged; minor biliary/fecal elimination. |
| Half-life | 2-3 hours for the immediate-release component; sustained-release formulation shows biphasic elimination with terminal half-life of 2-4 hours. |
| Protein binding | 10-15%, primarily to albumin. |
| Volume of Distribution | 0.5-1.5 L/kg; indicates extensive distribution into tissues. |
| Bioavailability | Oral sustained-release: 35-50% (first-pass metabolism); absolute bioavailability of immediate-release is 30-40%. |
| Onset of Action | Oral (sustained-release): 1-2 hours; peak effect at 4-6 hours. |
| Duration of Action | Approximately 7-8 hours for Ritalin-SR; clinical effect may last 6-10 hours depending on patient. |
| Molecular Weight | 269.34 |
20 mg orally twice daily, typically 30-45 minutes before breakfast and lunch; maximum 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment recommendations for GFR reduction; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased adverse effects. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use (no data). |
| Pediatric use | Children 6 years and older: initially 0.3-0.6 mg/kg/dose orally twice daily, with a maximum of 2 mg/kg/day or 60 mg/day. Dosing should be individualised. |
| Geriatric use | Start at 10 mg once daily in the morning; increase slowly based on tolerability and response; monitor for cardiovascular effects, insomnia, and weight loss. |
| 1st trimester | Methylphenidate is generally not recommended during first trimester due to lack of safety data and potential teratogenic risk; animal studies have shown adverse effects. |
| 2nd trimester | Limited data; may use if benefit outweighs risk; monitor for maternal hypertension and tachycardia. |
| 3rd trimester | Use with caution; may cause neonatal withdrawal (jitteriness, irritability) or respiratory distress; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for RITALIN-SR (RITALIN-SR).
| Placental transfer | Methylphenidate crosses the placenta; fetal plasma concentrations are approximately 20-30% of maternal levels. |
| Breastfeeding | Methylphenidate is excreted into breast milk in small amounts; relative infant dose is estimated at 0.2-0.7% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Epidemiologic studies have not shown increased risk of major congenital anomalies with methylphenidate, but there are reports of increased risk of cardiac malformations (RR ~1.3). Second/third trimesters: Exposure may be associated with increased risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding problems). Transient neonatal tachypnea and respiratory distress reported. |
| Fetal Monitoring | Monitor maternal weight gain, blood pressure, heart rate, and assess for anxiety or insomnia. Fetal monitoring: Serial growth ultrasounds (growth restriction risk), fetal heart rate monitoring, and neonatal assessment for withdrawal symptoms (irritability, tachypnea) after delivery. |
| Fertility Effects | Animal studies show reduced fertility with high doses (impaired spermatogenesis in males, prolonged estrous cycles in females). Human data limited, but no consistent evidence of impaired fertility. Use may be associated with decreased libido or erectile dysfunction, potentially affecting conception. |
■ FDA Black Box Warning
RITALIN-SR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse can cause sudden death or serious cardiovascular events.
| Serious Effects |
Known hypersensitivity to methylphenidate or any component of the formulationMarked anxiety, tension, or agitationGlaucomaTics or family history of Tourette's syndromeConcurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuationSevere hypertension, angina pectoris, cardiac arrhythmias, or other serious structural cardiac abnormalities
| Precautions | Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities, Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression, Seizures: risk may be increased in patients with prior seizure history or EEG abnormalities, Priapism: prolonged erections requiring immediate medical attention, Peripheral vasculopathy including Raynaud's phenomenon, Long-term suppression of growth in pediatric patients, Hematologic effects: monitor complete blood counts with differential during prolonged use |
| Food/Dietary | Food does not significantly affect absorption; however, high-fat meals may delay Tmax. Avoid alcohol, as it can alter the release characteristics and increase risk of adverse effects. No specific food restrictions, but maintain a balanced diet to counter appetite suppression. |
| Clinical Pearls | Ritalin-SR (methylphenidate sustained-release) has a duration of action of approximately 8 hours, due to a wax-matrix formulation. Avoid crushing or chewing tablets; they must be swallowed whole to preserve extended-release properties. Monitor for appetite suppression and weight loss in children. Use with caution in patients with a history of seizures, tics, or glaucoma. May exacerbate motor tics or Tourette syndrome. Avoid use within 2 weeks of MAO inhibitor therapy. Drug abuse potential requires careful prescription monitoring. |
| Patient Advice | Take Ritalin-SR exactly as prescribed, usually once daily in the morning. · Swallow the tablet whole; do not crush, chew, or break it. · Avoid taking this medication late in the day to prevent insomnia. · You may experience loss of appetite, weight loss, or stomach upset; take with food if stomach upset occurs. · Report any chest pain, palpitations, shortness of breath, or severe headache immediately. · Notify your doctor if you or your child develop tics or worsening of existing tics. · Do not stop abruptly without consulting your doctor to avoid withdrawal symptoms. · Store at room temperature away from moisture, heat, and light. · Keep this medication in a secure place to prevent misuse. |
Loading safety data…